Spero Therapeutics

Spero Therapeutics is developing novel therapies to treat highly resistant bacterial infections.  The company is in partnership with Roche to develop its first program targeting  gram-negative infections. Spero went public in November 2017 (NASDAQ: SPRO).

Headquarters Cambridge, MA
Website www.sperotherapeutics.com​
Twitter @Spero_Tx​
Pipeline Phase 1
Partners Roche, The National Institute of Allergy and Infectious Diseases (NIAID)